← Back to Clinical Trials
Recruiting NCT05177055

NCT05177055 Sleep in Psychiatric Care (SIP): Treatment for Comorbid Delayed Sleep-Wake Phase Disorder (DSWPD)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05177055
Status Recruiting
Phase
Sponsor Haukeland University Hospital
Condition Delayed Sleep-Wake Phase Disorder
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2022-05-23
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Group-based light therapy at gradually advanced timing for DSWPDGroup-based light therapy at gradually advanced timing for DSWPD and additive bb-glasses6-week wait list for sleep-school

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2022-05-23 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Sleep disorders commonly co-occur with psychiatric disorders. Sleep disorders are often treated with medication or not at all in psychiatric care, although there exist a plethora of documentation of the effectiveness of sleep interventions. There is also an increase in studies showing effectiveness of sleep-interventions when the sleep disorder co-occurs with psychiatric illness. The recommended treatment for Delayed Sleep-Wake phase disorder is light therapy at gradually advanced timing and/or melatonin administered in order to help phase-advance the circadian rhythm. There is a great gap in the knowledge on how sleep disorders can be treated effectively when they occur comorbid to moderate and severe psychiatric illness. In this project the we therefore seek to investigate the effect of psychological and behavioural, group-based treatment in a randomized controlled trial (RCT) where sleep and psychiatric symptoms are the primary outcome measures.

Eligibility Criteria

Inclusion Criteria: * Patients referred to the sleep-school at Bjørgvin DPS psychiatric hospital * Patients fulfilling the Diagnostic Manual for Mental Disorders (DSM-V) criteria for DSWPD comorbid to moderate to severe psychiatric illness (confirmed F-diagnosis based on the International Statistical Classification of Diseases and Related Health Problems (ICD-11) diagnostic system that are used in Norway in addition to DSWPD and/or scores of ≥19 on BDI and/or scores of ≥16 on BAI at the time of referral to the sleep school) Exclusion Criteria: * Night work * Patients that do not fulfil the DSM-V criteria for DSWPD comorbid to moderate to severe psychiatric illness (confirmed F-diagnosis based on the ICD-10 diagnostic system that are used in Norway in addition to insomnia and/or scores of ≥19 on BDI and/or scores of ≥16 on BAI at the time of referral to the sleep school)

Contact & Investigator

Central Contact

Ane Wilhelmsen-Langeland, PhD

✉ ane.wilhelmsen-langeland@helse-bergen.no

📞 +47 55957000

Principal Investigator

Ane Wilhelmsen-Langeland, PhD

PRINCIPAL INVESTIGATOR

Haukeland University Hospital

Frequently Asked Questions

Who can join the NCT05177055 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Delayed Sleep-Wake Phase Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05177055 currently recruiting?

Yes, NCT05177055 is actively recruiting participants. Contact the research team at ane.wilhelmsen-langeland@helse-bergen.no for enrollment information.

Where is the NCT05177055 trial being conducted?

This trial is being conducted at Bergen, Norway, Bergen, Norway.

Who is sponsoring the NCT05177055 clinical trial?

NCT05177055 is sponsored by Haukeland University Hospital. The principal investigator is Ane Wilhelmsen-Langeland, PhD at Haukeland University Hospital. The trial plans to enroll 60 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology